This chapter will describe the protocol used for the immunocytochemical (ICC) visualization of endothelin (ET) peptides, precursors and endothelin converting enzymes (ECEs) in both frozen cryostat tissue sections and cultured cells using polyclonal primary antisera raised in rabbits. We have raised antisera against the ET-1 carboxy-terminal heptapeptide, ET-1(15–21), which is conserved in all three ET isoforms, (thus, the antibody does not distinguish between the three mature peptides); big ET-1(31–38), big ET-2(31–37) and big ET-3(31–42) (1), the ECE-1 isoforms (2,3) and ECE-2 (4) (seeFig. 1). The specificity of these antisera have been characterized using radioimmunoassays (RIA, [5], seeChapter 2), enzyme-linked immunosorbant assays (ELISA, seeChapter 2) and in a comprehensive range of human and animal tissues using ICC, including comparisons with commercially available antibodies, although in most cases the staining achieved with these was less intense (1,6).
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.
Springer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
1.
Howard P. G., Plumpton C., and Davenport A. P. (1992) Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J. Hypertens.10, 1379–1386.PubMedCrossRefGoogle Scholar
2.
Davenport A. P., Kuc R. E., Plumpton C., Mockridge J. W., Barker P. J., and Huskisson N. S. (1998) Endothelin-converting enzyme in human tissues. Histochem. J.30, 359–374.CrossRefGoogle Scholar
3.
Mockridge J. W., Kuc R. E., Huskisson N. S., Barker P. J., and Davenport A. P. (1998) Characterization of site-directed antisera against endothelin-converting enzymes. J. Cardiovasc. Pharmacol.31, S35–S37.PubMedCrossRefGoogle Scholar
4.
Russell F. D. and Davenport A. P. (1999) Evidence for intracellular endothelinconverting enzyme-2 expression in cultured human vascular endothelial cells. Circ. Res.84, 891–896.PubMedGoogle Scholar
5.
Plumpton C., Ashby M. J., Kuc R. E., O’Reilly G., and Davenport A. P. (1996) Expression of endothelin peptides and mRNA in the human heart. Clin. Sci.90, 37–46.PubMedGoogle Scholar
6.
Cameron I. T., Davenport A. P., van Papendorp C., Barker P. J., Huskisson N. S., Gilmour R. S., et al. (1992) Endothelin-like immunoreactivity in human endometrium. J. Reprod. Fertil.95, 623–628.PubMedCrossRefGoogle Scholar
7.
Marciniak S. J., Plumpton C., Barker P. J., Huskisson N. S., and Davenport A. P. (1992) Localization of immunoreactive endothelin and proendothelin in the human lung. Pulm. Pharmacol.5, 175–182.PubMedCrossRefGoogle Scholar
8.
Bacon C. R. and Davenport A. P. (1996) Endothelin receptors in human coronary artery and aorta. Br. J. Pharmacol.117, 986–992.PubMedGoogle Scholar
9.
Cameron I. T., Plumpton C., Champeney R., van Papendorp C., Ashby M. J. and Davenport A. P. (1993) Identification of endothelin-1, endothelin-2 and endothelin-3 in human endometrium. J. Reprod. Fertil.98, 251–255.PubMedCrossRefGoogle Scholar
10.
Davenport A. P., Hoskins S. L., Kuc R. E., and Plumpton C. (1996) Differential distribution of endothelin peptides and receptors in human adrenal gland. Histochem. J.28, 779–789.PubMedCrossRefGoogle Scholar
11.
Plumpton C., Haynes W. G., Webb D. J., and Davenport A. P. (1995) Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. Br. J. Pharmacol.116, 1821–1828.PubMedGoogle Scholar
12.
Opgenorth T. J., Wu-Wong J. R., and Shiosaki K. (1992) Endothelin-converting enzymes. FASEB J.6, 2653–2659.PubMedGoogle Scholar
13.
Turner A. J. and Murphy L. J. (1996) Molecular pharmacology of endothelin converting enzymes. Biochem. Pharmacol.51, 91–102.PubMedCrossRefGoogle Scholar
14.
Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., Dewit D., and Yanagisawa M. (1994) ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell78, 473–485.PubMedCrossRefGoogle Scholar
15.
Shimada K., Matsushita Y., Wakabayashi K., Takahashi M., Iijima Y., and Tanzawa K. (1995a) Cloning and functional expression of endothelin-converting enzyme cDNA. Biochem. Biophys. Res. Commun.207, 807–812.PubMedCrossRefGoogle Scholar
16.
Shimada K., Takahashi M., Ikeda M., and Tanzawa K. (1995b) Identification of two isoforms of an endothelin-converting enzyme-1. Febs. Lett.371, 140–144.PubMedCrossRefGoogle Scholar
17.
Emoto N. and Yanagisawa M. (1995) Endothelin converting enzyme-2 is a membrane bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem.270, 15,262–15,268.PubMedCrossRefGoogle Scholar
18.
Davenport A. P. and Kuc R. E. (2000) Cellular expression of isoforms of endothelin converting enzyme (ECE-1c, ECE-1b and ECE-1a) and Endothelinconverting enzyme-2. J. Cardiovasc. Pharmacol.36, S12–S14.PubMedGoogle Scholar
19.
Russell F. D. and Davenport A. P. (1999) Evidence for intracellular endothelinconverting enzyme-2 expression in cultured human vascular endothelial cells. Circ. Res.84,8, 891–896.PubMedGoogle Scholar
20.
Russell F. D., Coppell A. L., and Davenport A. P. (1998) In vitro enzymatic processing of radiolabeled big ET-1 in human kidney. Biochem. Pharmacol.55, 697–701.PubMedCrossRefGoogle Scholar